Last reviewed · How we verify

NCT05203731

Level of Physical Activity and Fear Learning

Completed NA Last updated 27 February 2026
What this trial tests

NA trial testing Exercise in Generalized Anxiety Disorder in 54 participants. Completed in 19 March 2025.

Timeline
31 January 2023
Primary endpoint
19 March 2025
19 March 2025

Quick facts

Lead sponsorNYU Langone Health
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment54
Start date31 January 2023
Primary completion19 March 2025
Estimated completion19 March 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 60, any sex, with Generalized Anxiety Disorder or Social Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed experimental study will be the first to investigate whether exercise vs. sitting enhances consolidation of extinction learning in adults with high AS and anxiety disorders, and the mechanistic pathways of expectancy, affect, and key stress response markers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

Other recruiting trials for Generalized Anxiety Disorder

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing